"label","documentVersion","name","description","bcCategories","id","studyDesignRationale","studyInvestigationalInterventions","uuid:ID","studyEstimands"
"","","Study Design 1","The main design for the study","[]","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","[]","0219ebcd-f0ac-4915-bd51-a475b3e5fb1b","[]"
